Effectiveness of EGFR tyrosine kinase inhibitors in advanced non‐small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study

BACKGROUND: Epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) therapy is the standard treatment for advanced non‐small cell lung cancer (NSCLC) harboring common EGFR mutations, such as exon 19 deletion or L858 point mutation. However, the effectiveness of EGFR‐TKIs for patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanazu, Masaki, Mori, Masahide, Kimura, Madoka, Nishino, Kazumi, Shiroyama, Takayuki, Nagatomo, Izumi, Ihara, Shoichi, Komuta, Kiyoshi, Suzuki, Hidekazu, Hirashima, Tomonori, Kumagai, Toru, Imamura, Fumio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779206/
https://www.ncbi.nlm.nih.gov/pubmed/33124128
http://dx.doi.org/10.1111/1759-7714.13718

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7779206/
https://www.ncbi.nlm.nih.gov/pubmed/33124128
http://dx.doi.org/10.1111/1759-7714.13718

Ejemplares similares